ImmusanT start-up raises $20m to advance therapeutic vaccine for coeliac disease
This article was originally published in Scrip
ImmusanT, a US biotech which was launched in March 2011 from research which originated in Australia, has raised $20 million in a series A round of financing from Vatera Healthcare Partners of New York. It is developing an immunotherapeutic vaccine that would treat coeliac disease akin to allergy shots whereby repeated doses are used for desensitisation. The startup is also developing a companion diagnostic and monitoring tool for coeliac disease.